Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis

dc.contributor.authorKarlidag, Turgut
dc.contributor.authorCobanoglu, Bengu
dc.contributor.authorKeles, Erol
dc.contributor.authorAlpay, Hayrettin Cengiz
dc.contributor.authorOzercan, Ibrahim
dc.contributor.authorKaygusuz, Irfan
dc.contributor.authorSakallioglu, Oner
dc.date.accessioned2026-08-12T17:29:32Z
dc.date.issued2007
dc.departmentFırat Üniversitesi
dc.description.abstractObjective: The purpose of this study is to investigate the expression of Bax, p53, and p27/kip1 in patients with papillary thyroid carcinoma (PTC) with or without cervical nodal metastasis and to determine the role of immunohistochemical markers for prediction of neck metastasis in these patients. Study design and setting: A retrospective review from 1998 to 2004 at the Department of Otorhinolaryngology, Firat University, Elazig, Turkey, was performed in the records of 28 patients with nonmetastasizing (n = 15) and metastasizing (n = 13) PTC. The immunoreactivity, for Bax, p53, and p27/kip1 protein in all tissue specimens were assessed. Results: p27 expression in the nonmetastasizing PTC was lower than normal thyroid tissue (P <.01) and higher than metastasizing PTC (P <.01). p53 immunoreactivity was present, faint(grade 1) staining in a small number of cells in 2 nonmetastasizing PTCs. In 13 nonmetastasizing PTCs and all of metastasizing PTCs, normal thyroid tissue had no immunoreactivity for p53. There was no statistically significant difference among all groups' immunoreactivity for p53. Expression of Bax in patients with PTC was more than normal thyroid tissue (P <.01). However, expression of Bax in the patients with nonmetastasizing and metastasizing PTC was similar. Conclusion: The immunohistochemical evaluation of p27 expression in patients with PTC may be useful to predict for metastasis risk of the PTC to regional lymph nodes. (C) 2007 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.amjoto.2006.06.008
dc.identifier.endpage36
dc.identifier.issn0196-0709
dc.identifier.issue1
dc.identifier.orcid0000-0003-2744-2266
dc.identifier.orcid0000-0003-2748-7309
dc.identifier.pmid17162129
dc.identifier.scopus2-s2.0-33845348150
dc.identifier.scopusqualityQ2
dc.identifier.startpage31
dc.identifier.urihttps://doi.org/10.1016/j.amjoto.2006.06.008
dc.identifier.urihttps://hdl.handle.net/11508/55743
dc.identifier.volume28
dc.identifier.wosWOS:000243117700009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherW B Saunders Co-Elsevier Inc
dc.relation.ispartofAmerican Journal of Otolaryngology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectP27(Kip1) Expression
dc.subjectCancer
dc.subjectTumors
dc.subjectDisease
dc.subjectImpact
dc.subjectPrognosis
dc.subjectSurvival
dc.titleExpression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis
dc.typeArticle

Dosyalar